Generate a tailored SOP for Dr. Alison Michie. Improve your application with a focused, well-structured draft.
Alison Michie is a Professor at the University of Glasgow, where she leads the Molecular Lymphopoiesis group in the Paul O'Gorman Leukaemia Research Centre. Established in 2005, the group focuses on the molecular events that induce hematopoietic stem cells to commit to and differentiate into B and T lymphocyte lineages. Michie's research has defined the role of specific signaling molecules that control the early stages of B and T cell development, emphasizing the essential role of PKCα in mediating differentiation and proliferation signals downstream of the pre-TCR complex in vivo. Her future studies aim to investigate the mechanisms controlling normal and leukaemic cell development, identifying molecular events that initiate the development and maintenance of chronic lymphocytic leukaemia (CLL) in order to assist in the identification of novel therapeutic targets. Through collaborations with various academic and industrial partners, including GlaxoSmithKline, Michie's work employs experimental systems to validate the importance of novel targets in CLL and to test new therapeutic compounds using patient-derived samples. Her extensive contributions to the field encompass defining the mechanisms that lead to CLL phenotype and developing technologies to improve treatment outcomes for patients.